JZP541
Phase 2Withdrawn 1 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Irritability Associated With Autism Spectrum Disorder
Conditions
Irritability Associated With Autism Spectrum Disorder, Autism Spectrum Disorder, ASD
Trial Timeline
Jun 30, 2023 → Nov 9, 2023
NCT ID
NCT05733390About JZP541
JZP541 is a phase 2 stage product being developed by Jazz Pharmaceuticals for Irritability Associated With Autism Spectrum Disorder. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05733390. Target conditions include Irritability Associated With Autism Spectrum Disorder, Autism Spectrum Disorder, ASD.
What happened to similar drugs?
1 of 5 similar drugs in Irritability Associated With Autism Spectrum Disorder were approved
Approved (1) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
12
Activity
0
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05733390 | Phase 2 | Withdrawn |
Competing Products
7 competing products in Irritability Associated With Autism Spectrum Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KarXT + KarX-EC + KarXT + KarX-EC Matching Placebo | Bristol Myers Squibb | Phase 3 | 47 |
| KarXT + KarX-EC + KarXT + KarX-EC Matching Placebo | Bristol Myers Squibb | Phase 3 | 47 |
| Aripiprazole + Placebo | Bristol Myers Squibb | Approved | 43 |
| Brexpiprazole + Placebo | Lundbeck | Phase 3 | 37 |
| Brexpiprazole | Lundbeck | Phase 3 | 37 |
| Pimavanserin | Acadia Pharmaceuticals | Phase 2/3 | 27 |
| Pimavanserin + Placebo | Acadia Pharmaceuticals | Phase 2/3 | 35 |